
Sign up to save your podcasts
Or


Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
By Wondery4.6
1254312,543 ratings
Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

10,450 Listeners

30,218 Listeners

776 Listeners

467 Listeners

3,995 Listeners

19,234 Listeners

4,166 Listeners

19,096 Listeners

2,152 Listeners

2,949 Listeners

3,044 Listeners

22,948 Listeners

904 Listeners

1,466 Listeners

7,773 Listeners

256 Listeners

2,516 Listeners

251 Listeners

2,156 Listeners

7,394 Listeners

851 Listeners

1,526 Listeners

233 Listeners

594 Listeners

429 Listeners

66 Listeners

539 Listeners

876 Listeners

211 Listeners